StockData
Adial Pharmaceuticals, Inc. logo

Adial Pharmaceuticals, Inc. (AZR) shareholders

AZRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$3.67−0.15 (-3.81%)

Close on Nov 17, 2026Market cap $9.62MP/E –Yield –

Ownership

Who owns Adial Pharmaceuticals's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
5 buys · 0 sales
Net bought $106.33K

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Coastlands Capital LP
Joint filing with Coastlands Capital Partners LP (14.22%), Coastlands Capital GP LLC (14.22%) and 2 more
373,32214.22%13G (passive) amendmentJun 24, 2026
Coastlands Capital LLC
Joint filing with Coastlands Capital LP (9.98%), Coastlands Capital Partners LP (9.98%) and 2 more
262,1679.98%13G (passive)Jun 17, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Matt DavidsonPresident and CEO, Director923,74335.18%Nov 4, 2026
Tony GoodmanChief Operating Officer, Director26,5231.01%Apr 9, 2026
Cary J. ClaiborneChief Executive Officer, Director40,4171.54%Apr 9, 2026
Julie SaikiChief Strategy Officer761,63629.00%Nov 4, 2026
Vassiliki EconomidesChief Financial Officer––Oct 30, 2026
Vinay ShahChief Financial Officer17,3250.66%Apr 9, 2026
Aida HabtezionDirector––Nov 10, 2026
Paul J. HastingsDirector––Nov 10, 2026
Thomas M. SolowayDirector––Nov 10, 2026
Wendy B. YoungDirector––Sep 21, 2026
Kevin SchuylerDirector9,4470.36%Apr 9, 2026
J. Kermit AndersonDirector––Apr 9, 2026
Robertson H. GillilandDirector104,6093.98%Apr 9, 2026
James W. Newman Jr.Director338,46312.89%Jun 2, 2025
Capital LP Coastlands10% owner388,30814.79%Nov 3, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Matt Davidson
President and CEO, Director
Nov 2, 2026Conversion+101,298––104,725
Matt Davidson
President and CEO, Director
Nov 2, 2026Conversion+524,954––819,018
Julie Saiki
Chief Strategy Officer
Nov 2, 2026Conversion+626,252––761,636
Matt Davidson
President and CEO, Director
Oct 28, 2026Award+232,417––294,064
Capital LP Coastlands
10% owner
Jul 16, 2026Buy+1,233$2.75$3.39K388,308
Capital LP Coastlands
10% owner
Jul 14, 2026Buy+2,000$2.65$5.30K387,075
Capital LP Coastlands
10% owner
Jul 10, 2026Buy+1,700$2.70$4.59K385,075
Capital LP Coastlands
10% owner
Jul 9, 2026Buy+10,053$2.79$28.05K383,375
Capital LP Coastlands
10% owner
Jun 29, 2026Buy+25,000$2.60$65.00K373,322
Matt Davidson
Chief Development Officer, Director
Jun 12, 2026Award+232,417––297,491
Matt Davidson
Chief Development Officer, Director
Jun 11, 2026Award+61,647––61,647
Matt Davidson
Chief Development Officer, Director
Jun 11, 2026Award+1,822.13––1,822
Matt Davidson
Chief Development Officer, Director
Jun 11, 2026Award+101.3––1,923
Matt Davidson
Chief Development Officer, Director
Jun 11, 2026Award+3,427––3,427
Tony Goodman
Chief Operating Officer, Director
Apr 7, 2026Award+26,510––26,523
Vinay Shah
Chief Financial Officer
Apr 7, 2026Award+17,325––17,325
Kevin Schuyler
Director
Apr 7, 2026Award+9,185––9,213
Cary J. Claiborne
Chief Executive Officer, Director
Apr 7, 2026Award+37,985––40,417
Robertson H. Gilliland
Director
Apr 7, 2026Award+9,185––9,185
Kevin Schuyler
Director
Sep 29, 2023Buy+700$2.74$1.92K700
William B. Stilley III
Director
May 23, 2023Award+240,800––1,261,779
Joseph Truluck
Chief Financial Officer
May 23, 2023Award+157,500––265,139
Cary J. Claiborne
Chief Executive Officer, Director
May 23, 2023Award+420,000––1,520,000
William B. Stilley III
Director
Dec 30, 2022Returned to company−166,667––1,020,979
Cary J. Claiborne
Chief Executive Officer, Director
Sep 20, 2022Award+75,000$0.42$31.50K1,100,000
Cary J. Claiborne
Chief Executive Officer, Director
Sep 19, 2022Award+25,000$0.43$10.75K1,025,000
Cary J. Claiborne
Chief Executive Officer
Aug 18, 2022Award+1,000,000––1,000,000
William B. Stilley III
Chief Executive Officer, Director
Feb 23, 2022Award+250,000––1,187,646
James W. Newman Jr.
Director
Dec 30, 2021Buy+10,000$2.71$27.10K34,644
James W. Newman Jr.
Director
Dec 30, 2021Buy+5,000$2.72$13.60K50,221
James W. Newman Jr.
Director
Dec 30, 2021Buy+10,000$2.66$26.60K20,000
Kevin Schuyler
Director, 10% owner
Dec 23, 2021Gift−312,990––0
William B. Stilley III
Chief Executive Officer, Director, 10% owner
Nov 30, 2021Buy+10,600$2.75$29.15K937,646
William B. Stilley III
Chief Executive Officer, Director, 10% owner
Nov 29, 2021Buy+10,000$2.59$25.90K927,046
James W. Newman Jr.
Director
Nov 26, 2021Buy+10,000$2.85$28.50K34,475
Bankole A. Johnson
Chief Medical Officer
Oct 4, 2021Sale−200,000––148,246
Bankole A. Johnson
Chief Medical Officer
Apr 6, 2021Sale−150,000$2.50$375.00K548,336
James W. Newman Jr.
Director
Jan 26, 2021Award+1,187––14,475
James W. Newman Jr.
Director
Jan 26, 2021Award+2,544––152,963
William B. Stilley III
Chief Executive Officer, Director, 10% owner
Jan 26, 2021Award+201,109––917,046
Bankole A. Johnson
Chief Medical Officer
Aug 20, 2020Sale−350,000$1.21$423.50K1,055
James W. Newman Jr.
Director
Mar 27, 2020Buy+5,000$1.42$7.10K15,000
James W. Newman Jr.
Director
Mar 27, 2020Buy+4,644$1.35$6.27K14,644
James W. Newman Jr.
Director
Mar 27, 2020Buy+10,000$1.34$13.40K13,288
William B. Stilley III
Chief Executive Officer, Director, 10% owner
Mar 26, 2020Buy+12,652$1.47$18.60K715,937
William B. Stilley III
Chief Executive Officer, Director, 10% owner
Mar 25, 2020Buy+12,348$1.13$13.95K703,285
William B. Stilley III
Chief Executive Officer, Director, 10% owner
Mar 3, 2020Award+54,167––690,937
Joseph Truluck
Chief Financial Officer, Director
Mar 3, 2020Award+27,084––107,639
Bankole A. Johnson
Chief Medical Officer, 10% owner
Dec 12, 2019Sale−150,000$1.00$150.00K698,336
Bankole A. Johnson
Chief Medical Officer, 10% owner
Oct 2, 2019Award+3,187––351,055
Bankole A. Johnson
Chief Medical Officer, 10% owner
Mar 29, 2019Buy+30,000$3.47$104.10K344,768
Bankole A. Johnson
Chief Medical Officer, 10% owner
Mar 29, 2019Buy+2,500$3.47$8.68K347,268
Bankole A. Johnson
Chief Medical Officer, 10% owner
Mar 29, 2019Buy+600$3.30$1.98K347,868
Bankole A. Johnson
Chief Medical Officer, 10% owner
Mar 28, 2019Buy+40,000$3.15$126.00K314,768
Kevin Schuyler
Director
Jul 31, 2018Buy+90,000––312,990
Kevin Schuyler
Director
Jul 31, 2018Other+89,600––222,990
Kevin Schuyler
Director
Jul 31, 2018Other+144,200––144,200
Tony Goodman
Director
Jul 31, 2018Buy+7,000––8,755
Joseph Truluck
Chief Financial Officer
Jul 31, 2018Conversion+5,927––80,555
Robertson H. Gilliland
Director
Jul 31, 2018Conversion+29,931––95,424

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
43.51%
0M shares short
Days to cover
4.1
At 0M shares a day
Change since last report
+20.9%
From 0M shares
Short volume, 12 days
17.6%
Of volume reported to FINRA

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Adial Pharmaceuticals's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?